
Retinal Pharmacotherapy
Saunders (Publisher)
Published on 16. March 2010
Book
Hardback
408 pages
978-1-4377-0603-1 (ISBN)
Description
Retinal Pharmacotherapy is the first comprehensive book devoted to pharmacologic agents and their rationale and mechanisms of action in selected retinal and uveitic diseases. Drs. Quan Dong Nguyen, Eduardo Buchele Rodrigues, Michel Eid Farah, and William F. Mieler lead an international team of expert contributors to present up-to-date knowledge of new drugs on the market, the science behind the drugs, evidence of how the drugs work, and the reasons why they are effective or not. This user-friendly, all-in-one reference provides you with easy access to practical information on the effective and appropriate use of pharmacologic agents in the management of retinal diseases.
Covers all new and existing retinal drugs to keep you current in this expanding area of the treatment of retinal diseases.
Discusses the background behind retinal drugs and the various pathways of how they work so you can make thoroughly informed clinical decisions.
Presents 400 color photographs and line drawings that illustrate disease appearance before and after treatment and clarify difficult key concepts.
Features contributors from Europe, North America, South America, the Middle East, Asia, and Australia for an international approach.
Identifies and emphasizes key points clearly in each chapter to improve comprehension and make finding information easier.
Covers all new and existing retinal drugs to keep you current in this expanding area of the treatment of retinal diseases.
Discusses the background behind retinal drugs and the various pathways of how they work so you can make thoroughly informed clinical decisions.
Presents 400 color photographs and line drawings that illustrate disease appearance before and after treatment and clarify difficult key concepts.
Features contributors from Europe, North America, South America, the Middle East, Asia, and Australia for an international approach.
Identifies and emphasizes key points clearly in each chapter to improve comprehension and make finding information easier.
More details
Language
English
Place of publication
Philadelphia
United States
Publishing group
Elsevier - Health Sciences Division
Target group
Professional and scholarly
Illustrations
Approx. 407 illustrations (320 in full color)
Dimensions
Height: 281 mm
Width: 222 mm
ISBN-13
978-1-4377-0603-1 (9781437706031)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Persons
possui gradua??o em Medicina pela Universidade Federal de Santa Catarina (1998), resid?ncia m?dica no Hospital S?o Jos? (1999-2001), especializa??o em doen?as da retina na Universidade Federal de Goi?s/Centro Brasileiro de Cirurgia de Olhos (2001), especializa??o em doen?as da retina na Universidade Philipps-Universitaet Marburg na Alemanha (2002-2004), especializa??o em Oncologia Ocular pela Thomas Jefferson University/ Wills Eye Hospital, Philadelphia EUA (2004-2005), doutorado em Oftalmologia pela Universidade Philipps-Universitaet (2004) e doutorado em Oftalmologia pela Universidade Federal de S?o Paulo (2011). Atualmente ? m?dico respons?vel pelo Servi?o de Oncologia Ocular do CEPON / Centro de Pesquisas Oncol?gicas do Estado de Santa Catarina. Trabalha como m?dico e pesquisador na Universidade Federal de S?o Paulo onde realiza seu p?s-doutorado. Tem experi?ncia na ?rea de Oftalmologia com ?nfase no diagn?stico e tratamento de doen?as da m?cula, retina, v?treo assim como tumores oculares. Gabriel Costa de Andrade Possui gradua??o em Medicina pela Faculdade de Medicina de S?o Jos? do Rio Preto - FAMERP (2003-2008). Resid?ncia m?dica em Oftalmologia pela FAMERP (2009-2012). T?tulo de especialista em Oftalmologia conferido pelo MEC (2012). T?tulo de especialista em Oftalmologia conferido pelo CBO (Conselho Brasileiro de Oftalmologia) (2012). Especializa??o em Retina e V?treo - CBEO - Araraquara (2012). Especializa??o em Retina e V?treo - RETINA CLINICA - S?o Paulo (2012-2014). Especializa??o em M?cula - UNIFESP - S?o Paulo (2014). Especializa??o em Uve?tes (em andamento) - UNIFESP - S?o Paulo. P?s-graduando n?vel doutorado em Retina (em andamento) - UNIFESP - S?o Paulo. Bolsista de Produtividade em Pesquisa 1B Possui gradua??o pela Faculdade de Medicina do ABC (1978), Resid?ncia em Oftalmologia no Hospital dos Servidores do Estado do Rio de Janeiro (1981), Mestrado em Oftalmologia pela UNIFESP / EPM (1987), Doutorado em Oftalmologia pela UNIFESP / EPM (1991) e Livre-doc?ncia em Oftalmologia em 1998 pela UNIFESP / EPM. Realizou Fellowship na ?rea de pesquisa em Retina e V?treo no Bascom Palmer Eye Institute, Universidade de Miami, EUA (1983). Orientador de 11 Mestrados, 22 Doutorados e dois P?s-Doutorados - 27 orienta??es conclu?das e aprovadas (total de 35). Participou de 48 bancas de Tese (34 de Doutorado e 14 de Mestrado). ? Professor Adjunto, orientador da P?s-Gradua??o e Vice-Chefe do Departamento de Oftalmologia da UNIFESP / EPM. Foi Diretor Academico do Curso de Tecnologia Oft?lmica por quatro anos por duas gest?es consecutivas de 2002 a 2004. Possui 196 artigos cient?ficos publicados na ?ntegra em peri?dicos com crit?rio editorial de sele??o por pares (106 no exterior e 90 no Brasil) e 476 trabalhos publicados em anais de eventos (192 no exterior e 284 no Brasil). Apresenta ?ndice H 20 de acordo com o Publish or Perish (1136 cita??es), 16 do Scopus (790 cita??es) e 18 da Web of Science (863 cita??es). Publicou tr?s livros e 127 cap?tulos de livros. Registrou tr?s patentes. Participou de 70 Congressos e Simp?sios no Exterior e 133 no Brasil. Recebeu 58 Pr?mios e / ou Homenagens (13 no Exterior e 45 no Brasil). Foi Presidente da Sociedade Brasileira de Retina e V?treo. ? Secret?rio da Sociedade Panamericana de Retina e V?treo. Membro do Club Jules Gonin, da Macula Society, da Sociedade Americana de Especialistas em Retina, da Sociedade Americana de Retina e da Sociedade Europ?ia de Retina. Dedica-se ao estudo, pesquisa e tratamento especializado das doen?as da retina em geral, m?cula e v?treo h? 25 anos. Participou de mais de 20 ensaios cl?nicos multic?ntricos randomizados, v?rios como Investigador Principal. Coordenou e ou coordena projetos cient?ficos junto a diversas ag?ncias de fomento, tais como FAPESP, CNPq, FINEP, CAPES, FADA e JNICT. Foi coordenador do Projeto Tem?tico Avalia??o das Altera??es da Vasculatura da Retina e Coroide pela Angiografia Din?mica Computadorizada com Fluoresce?na S?dica e Indocianina Verde (FAPESP) e da Implanta??o de Unidade Avan?ada de Alta Complexidade em Ensino e Pesquisa de Cl?nica e Cirurgia de Retina (FINEP). Atua na ?rea de Telemedicina como Pesquisador de Triagem Autom?tica de Retinopatias Diab?ticas, Tecnologia da Informa??o Contra a Cegueira Preven?vel (FAPESP- Microsoft). Foi coordenador durante sete anos e supervisor pelos ?ltimos cinco anos do Programa Mutir?o Olho Diab?tico. ? Presidente do Instituto da Vis?o (IPEPO). Indicado para a Confer?ncia American Journal of Ophthalmology na reuni?o conjunta da Academia Americana de Oftalmologia e Associa??o Panamericana de Oftalmologia (S?o Francisco) em 2009
Content
1 Evolving Knowledge in Pharmacologic Treatments
Section 1: Basic Sciences in Retina
2 Retinal Anatomy and Pathology
3 Retinal Biochemistry, Physiology and Cell Biology
4 Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors
5 Ocular Immunity and Inflammation
6 Complement Activation and Inhibition in Retinal Disease
7 Genetics of Retinal Disease
Section 2: Animal Models and Routes for Retinal Drug Delivery
8 Vitamins and Supplements for Age-Related Macular Degeneration
9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems
0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy
11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal Gas-Phase Nanoparticles
12 Routes for Drug Delivery: Sustained-Release Devices
13 Microspheres and Nanotechnology for Drug Delivery
14 Thermo-sensitive Hydrogels
15 Retina and Ocular Toxicity to Ocular Application of Drugs
16 Retinal Toxicity of Systemic and Topical Medications
Section 3: Retinal Diseases Amenable to Pharmacotherapy
17 Non-neovascular Age-Related Macular Degeneration
18 Neovascular Age-Related Macular Degeneration
19 Diabetic Retinopathy and Diabetic Macular Edema
20 Retinal Vein Occlusion
21 Retinal Detachment and Proliferative Vitreoretinopathy
22 Posterior Uveitis
23 Choroidal Neovascularization Secondary to Inflammation, Infection, and Myopia
24 Ocular Infection: Endophthalmitis
25 Retinopathy of Prematurity
26 Idiopathic Macular Telangiectasia
27 Neovascular Glaucoma
28 Retinal Hereditary and Degenerative / Dystrophic Diseases (non-AMD)
Section 4: Drugs and Mechanisms in Retinal Diseases
29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Retinal Diseases
30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others
31 Anecortave Acetate
32 Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab
33 Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab
34 Pathophysiology of Vascular Endothelial Growth Factor and Other Angiogenic Molecules
35 Biologic Therapies: Infliximab, Adalimumab, Etanercept, Daclizumab, and Others
36 Immunomodulatory Therapy in Uveitis
37 Fusion Proteins: VEGF-Trap
38 Aptamers and Intramers: Pegaptanib
39 Protein Kinase C Inhibitor: Ruboxistaurin
40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP
41 Ocular Gene Therapy
42 Neuroprotection and Retinal Diseases
43 Photosensitizers and Photodynamic Therapy: Verteporfin
44 Chemotherapy for Malignant Intraocular Tumors
45 Antibiotics
Section 5: Pharmacotherapy and Surgery
46 Rheotherapy (Rheopheresis; Therapeutical Apheresis)
47 Enzymatic Vitrectomy and Pharmacologic Vitreodynamics
48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy
49 Epimacular and External Radiotherapy
50 Current Status of Human Retinal Pigment Epithelial Transplantation
Section 6: The Last Words
51 Off-Label Drugs and the Impact of the Food and Drug Administration in the Treatment of Retinal Disease
52 Value-Based Medicine and Pharmacoeconomics
53 Future Perspectives: Agents on the Horizon
Section 1: Basic Sciences in Retina
2 Retinal Anatomy and Pathology
3 Retinal Biochemistry, Physiology and Cell Biology
4 Ocular Angiogenesis: Vascular Endothelial Growth Factor and Other Factors
5 Ocular Immunity and Inflammation
6 Complement Activation and Inhibition in Retinal Disease
7 Genetics of Retinal Disease
Section 2: Animal Models and Routes for Retinal Drug Delivery
8 Vitamins and Supplements for Age-Related Macular Degeneration
9 Ocular Pharmacokinetic, Drug Bioavailability and Intraocular Drug Delivery Systems
0 Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections and Vitrectomy
11 Routes for Drug Delivery: Topical, Transscleral, Suprachoroidal, and Intravitreal Gas-Phase Nanoparticles
12 Routes for Drug Delivery: Sustained-Release Devices
13 Microspheres and Nanotechnology for Drug Delivery
14 Thermo-sensitive Hydrogels
15 Retina and Ocular Toxicity to Ocular Application of Drugs
16 Retinal Toxicity of Systemic and Topical Medications
Section 3: Retinal Diseases Amenable to Pharmacotherapy
17 Non-neovascular Age-Related Macular Degeneration
18 Neovascular Age-Related Macular Degeneration
19 Diabetic Retinopathy and Diabetic Macular Edema
20 Retinal Vein Occlusion
21 Retinal Detachment and Proliferative Vitreoretinopathy
22 Posterior Uveitis
23 Choroidal Neovascularization Secondary to Inflammation, Infection, and Myopia
24 Ocular Infection: Endophthalmitis
25 Retinopathy of Prematurity
26 Idiopathic Macular Telangiectasia
27 Neovascular Glaucoma
28 Retinal Hereditary and Degenerative / Dystrophic Diseases (non-AMD)
Section 4: Drugs and Mechanisms in Retinal Diseases
29 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in the Treatment of Retinal Diseases
30 Corticosteroids: Triamcinolone, Dexamethasone, Fluocinolone, and Others
31 Anecortave Acetate
32 Therapeutic Monoclonal Antibodies and Fragments: Bevacizumab
33 Therapeutic Monoclonal Antibodies and Fragments: Ranibizumab
34 Pathophysiology of Vascular Endothelial Growth Factor and Other Angiogenic Molecules
35 Biologic Therapies: Infliximab, Adalimumab, Etanercept, Daclizumab, and Others
36 Immunomodulatory Therapy in Uveitis
37 Fusion Proteins: VEGF-Trap
38 Aptamers and Intramers: Pegaptanib
39 Protein Kinase C Inhibitor: Ruboxistaurin
40 Small-Interference RNA Technology: SIRNA 027, Bevasiranib, and REDD14NP
41 Ocular Gene Therapy
42 Neuroprotection and Retinal Diseases
43 Photosensitizers and Photodynamic Therapy: Verteporfin
44 Chemotherapy for Malignant Intraocular Tumors
45 Antibiotics
Section 5: Pharmacotherapy and Surgery
46 Rheotherapy (Rheopheresis; Therapeutical Apheresis)
47 Enzymatic Vitrectomy and Pharmacologic Vitreodynamics
48 The Use of Vital Dyes during Vitreoretinal Surgery - Chromovitrectomy
49 Epimacular and External Radiotherapy
50 Current Status of Human Retinal Pigment Epithelial Transplantation
Section 6: The Last Words
51 Off-Label Drugs and the Impact of the Food and Drug Administration in the Treatment of Retinal Disease
52 Value-Based Medicine and Pharmacoeconomics
53 Future Perspectives: Agents on the Horizon